Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.
For patients with metastatic prostate cancer, bone is the primary site of tumor localization and the major cause of disease-related morbidity and mortality. Hormonal therapy and chemotherapy alone cannot eradicate disease harbored in bone. The delivery of radiotherapy to the reservoir of disease is an approach previously only achievable using bone-seeking radiopharmaceuticals. Now, however, with the identification of tumor-specific targets, antibodies are being used to deliver radiotherapy to these sites. In this article, we review the rationale behind this approach, the targets being explored, the radiation sources available, and the antibodies currently under clinical development.
Morris
Michael J
MJ
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 444, New York, NY 10021, USA. morrism@mskcc.org
Pandit-Taskar
Neeta
N
Divgi
Chaitanya
C
Larson
Steven
S
Scher
Howard I
HI
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000276:immunology / Q000532:radiotherapy* / Q000556:secondary*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology* / Q000532:radiotherapy*; D011788:Quality of Life; D016499:Radioimmunotherapy / Q000379:methods*; D019275:Radiopharmaceuticals / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D007155:Immunologic Factors; D019275:Radiopharmaceuticals